Brief: Basilea Pharmaceutica Expects Revenue To Rise 5.5% To CHF 220 Mln in 2025

Basilea Pharmaceutica AG, Allschwil

18/02/2025 06:19

Feb 18 (Reuters) - BASILEA PHARMACEUTICA AG  BSLN.S :
    * OUTLOOK 2025: TOTAL REVENUE IS EXPECTED TO INCREASE BY
5.5% TO
CHF 220 MILLION DRIVEN BY AN INCREASE IN BARDA AND CARB-X
REIMBURSEMENTS
    * OUTLOOK 2025: MILESTONE AND UPFRONT PAYMENTS IN 2025 ARE
EXPECTED TO BE IN AVERAGE RANGE OF LAST FEW YEARS OF AROUND CHF
35 MILLION
    * OUTLOOK 2025: EXPECT TO MAINTAIN HIGH OPERATING PROFIT
LEVEL OF
2024
    * OUTLOOK 2025: 12% INCOME TAX RATE WILL BE REFLECTED IN
2025 NET
PROFIT
    * AFTER SERVING ON BOARD OF DIRECTORS FOR 14 YEARS, DOMENICO
SCALA
HAS DECIDED NOT TO STAND FOR RE-ELECTION
    * BOARD HAS NOMINATED STEPHAN SCHINDLER FOR ELECTION AS A
NEW
BOARD MEMBER AND CHAIRMAN

Source text:  ID:nGNXbB945K 
Further company coverage:  BSLN.S 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))